.png)
Agenzia Italiana del Farmaco
home
Highlights
-
31 Mar 2023
Innovative medicinal products
Innovative medicines list: AIFA publishes February 2023 update
AIFA updates the list of medicines that, in the opinion of the Scientific and Technical Committee (CTS), meet the requirement of full or conditional therapeutic innovativeness.
-
28 Mar 2023
Monitoring Registers
Monitoring of antivirals for COVID-19: new report published
The Italian Medicines Agency (AIFA) has published the results of the monitoring of antivirals currently available for treating COVID-19.
-
28 Mar 2023
Monitoring Registers
Hepatitis C: update of 27 March 2023 concerning enrolled patients
AIFA has published the updated weekly data concerning treatments with new second-generation direct acting antiviral agents (DAAs) for chronic hepatitis C, as collected by AIFA Monitoring registries.
-
23 Mar 2023
Monitoring Registers
Monitoring of monoclonal antibodies for COVID-19: weekly report published
AIFA publishes the results of the monitoring related to monoclonal antibodies for the treatment of COVID-19 currently available.
News
31 Mar 2023
Safety of medicinal products
Direct communication with healthcare professionals on Minirin/DDAVP (desmopressin)
27 Mar 2023
Information and communication
Italian Medicines Agency's online services will be unavailable due to scheduled maintenance
22 Mar 2023
Monitoring pharmaceutical expenditure
Monitoring of Pharmaceutical expenditure (January / November 2022)
20 Mar 2023
Monitoring Registers
Hepatitis C: update of 20 March 2023 concerning enrolled patients
16 Mar 2023
Safety of medicinal products
Direct communication with healthcare professionals on Janus kinase inhibitors (JAKi)
06 Mar 2023
Access to medicinal products
Direct communication with healthcare professionals on Ozempic® (semaglutide)
FarmaciLine
Questions regarding drug efficacy, safety and availability
TOLL-FREE NUMBER
Servizi Utili
Interactive OsMed - The use of medicines in Italy
An interactive consultation of data on the use of medicines in Italy in the general and regional population, described in terms of expenditure, volumes, typology
